Catalyst Calendar

Thu, May 28, 2026

1 updates

4:01 PM

Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Support U.S. Biodefense Strategy

GAITHERSBURG, Md., May 28, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has been awarded a contract modification valued at approximately $64.5 million from the Administration for Strategic Preparedness and Response (ASPR), a division of the United States

emergentbiosolutions.com

Wed, May 20, 2026

1 updates

EBS

7:30 AM

Emergent BioSolutions to Participate in Upcoming Investor Conferences

GAITHERSBURG, Md., May 20, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s senior management team will participate in the following investor conferences: Goldman Sachs 11th Annual Leveraged Finance and Credit Conference, May 27-29

emergentbiosolutions.com

Mon, May 18, 2026

1 updates

EBS

8:59 AM

Emergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live]

GAITHERSBURG, Md., May 18, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS), a global biodefense company, today announced that the Saudi Food and Drug Authority (SFDA) has approved the registration of ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live], for the prevention of smallpox

emergentbiosolutions.com

Thu, Apr 30, 2026

2 updates

EBS

4:30 PM

Emergent BioSolutions Reports First Quarter 2026 Financial Results

First Quarter 2026 Total Revenues of $156.1 million First Quarter 2026 Net Income of $6.8 million and Net Income Margin of 4% First Quarter 2026 Adjusted EBITDA of $35.6 million and Adjusted EBITDA Margin of 23% GAITHERSBURG, Md., April 30, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc.

emergentbiosolutions.com

EBS

7:55 AM

Emergent BioSolutions Receives Approval from Singapore Health Sciences Authority for Expanded Indication of ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) to Include Mpox

GAITHERSBURG, Md., April 30, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that Singapore’s Health Sciences Authority (HSA) has approved an expanded indication for ACAM2000 ® (Smallpox and Mpox (Vaccinia) Vaccine, Live) to include prevention of mpox disease in

emergentbiosolutions.com

Wed, Apr 29, 2026

2 updates

EBS

7:35 AM

Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142

GAITHERSBURG, Md., April 29, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced a multi-year agreement with SAB Biotherapeutics, Inc. (Nasdaq: SABS, SAB BIO) to support the process development and manufacturing of SAB-142, SAB BIO’s lead program in clinical development

emergentbiosolutions.com

EBS

6:53 AM

Emergent BioSolutions Partners with Professional Baseball Player Davis Schneider to Raise Awareness of NARCAN® Nasal Spray Among Canadians and Help Save Lives

Star left fielder joins forces with Emergent to educate the public on the importance of being prepared with NARCAN ® Nasal Spray Schneider shares his family’s story as part of Emergent’s Opioid Crisis Impact Map WINNIPEG, Manitoba, April 29, 2026 (GLOBE NEWSWIRE) -- Today, Emergent BioSolutions

emergentbiosolutions.com

Tue, Apr 28, 2026

1 updates

EBS

8:01 AM

Emergent BioSolutions and Substipharm Biologics Announce Strategic Manufacturing Partnership to Support Japanese Encephalitis Vaccine in the United States

Emergent’s Canton facility will manufacture drug substance and obtains exclusive distribution rights GAITHERSBURG, Md. and GENEVA, April 28, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has entered into an agreement with Substipharm Biologics valued at

emergentbiosolutions.com

Thu, Apr 16, 2026

2 updates

EBS

4:05 PM

Emergent BioSolutions Successfully Refinances Term Loan, Amends Asset-backed Loan Facility and Increases Financial Flexibility

Refinancing extends maturities, reduces interest expense and positions Emergent for durable, long-term growth as part of its multi-year transformation plan GAITHERSBURG, Md., April 16, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that the company has closed on a

emergentbiosolutions.com

EBS

4:05 PM

Emergent BioSolutions to Report First Quarter 2026 Financial Results on April 30, 2026

GAITHERSBURG, Md., April 16, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, April 30, 2026, at 5:00 p.m. eastern time to discuss the financial results for the first quarter of 2026. Participants can access the conference call live via

emergentbiosolutions.com